10x Genomics: The Market Sees Flat Revenue. The Cash Flow Says Something Different.

10x Genomics reported Q2 2026 revenue of $151 million — barely above the $146.5 million consensus — and instrument revenue collapsed 47% year-over-year. The stock fell 3.9% on the print, as if to confirm what the headlines say: this is a company struggling to grow while it waits for a product that hasn't shipped.

That's the old story. And the market is still pricing it.

The proof path doesn't live in the top line this quarter. It lives in the cash flow.

The headline vs. the engine

Q2 consumables revenue grew 7% year-over-year. Spatial consumables — driven by Xenium utilization — grew 16%. Single-cell consumables grew 3%, supported by double-digit reaction volume growth on the Flex Apex platform. Consumables is the recurring revenue engine; instruments are the one-time entry point. When instruments fall and consumables rise, it usually means either customers are abandoning the ecosystem or they're sitting on installed hardware and running more samples.

10x Genomics is in the second camp. And the cash flow tells you why.

Trailing-twelve-month free cash flow hit $122.2 million — up 175% year-over-year. The FCF margin was 19.1%. Operating cash flow was $127.8 million against capital expenditures of just $5.6 million. That is an extraordinarily low capex footprint for a company building biophysics instruments. The business prints cash while it builds the next product.

Gross margin expanded to 74% in Q2, up from 72% a year ago. Excluding a small non-recurring Takara settlement, margin was 74% versus 67% in Q2 2025, helped by $2.6 million in tariff refunds and lower inventory write-downs. The margin expansion is structural, not just a one-off.

GAAP operating margin came in at negative 12.9%, which looks terrible until you notice that Q2 2025 included $40.7 million in patent litigation gains. Strip those out and operating expenses were approximately flat year-over-year. EPS was -$0.14 versus consensus of -$0.25 — a 43% beat on a negative number, but a beat nonetheless.

The company ended the quarter with $552 million in cash and marketable securities, up $105 million year-over-year. Total debt sits at $201 million. This is not a company that needs to raise capital.

Atera is the bridge

The instrument collapse is not demand failure. It's a deliberate transition. Customers deferred Chromium and Visium/Xenium purchases in advance of the Atera launch and tariff uncertainty. 10x Genomics has been clear about this for two quarters straight.

Atera is the company's new spatial whole-transcriptome platform — higher sensitivity than Xenium, single-cell resolution across intact tissue. Management says customer response "exceeded expectations." Booked orders as of end of Q2 already exceeded the full-year 2026 shipment target of approximately 40 units. Shipments are constrained by manufacturing capacity, not demand.

That constraint is the detail worth sitting with. In a business where recurring consumables revenue is the profit engine, demand outstripping supply is unusual. It doesn't happen by accident.

Here's why the installed base matters. Management estimates Atera potential utilization at roughly 2x Xenium levels — between $0.5 million and $3 million in consumables annually per instrument, depending on assay mix. Xenium itself is the spatial consumables growth driver, and that line grew 16% in Q2 alone.

Forty Atera units shipping, weighted to Q4, at even the conservative end of that utilization range means a meaningful incremental recurring revenue stream starting in 2027. The company's full-year revenue guidance of $620 million at the midpoint came in 1% above analysts’ estimates, but the guidance envelope doesn't fully capture the consumables pull-through from Atera because those instruments won't meaningfully ship until Q4.

The real Atera story plays out in 2027, not 2026.

Where the market is still wrong

Wall Street consensus expects EPS to worsen from -$0.59 to -$0.78 over the next twelve months. That forecast assumes revenue grows roughly 3.6% and costs keep expanding. It's pricing a company that's burning cash while it waits.

The cash flow says otherwise. FCF grew 175% last year. The company is adding cash, not consuming it. Atera orders outpace manufacturing. Consumables growth is accelerating in spatial (16%) and holding steady in single-cell (3% with double-digit reaction volumes). Gross margin expanded despite the transition headwind.

The earnings deterioration Wall Street models is driven by one-time litigation gains disappearing from the GAAP comparison, not by a deteriorating operating trajectory. Ex-litigation, operating expenses were flat. The business isn't getting worse — the prior-year comparison is just getting honest.

The valuation question

This is the part that complicates things. The stock has surged 180% year-to-date, up from a 52-week low of $11.16 to the current price near $45.60. Market cap is roughly $5.8 billion.

The stock trades at 9.1 times trailing sales and roughly 47 times trailing free cash flow ($5.8B market cap / $122M FCF). Those aren't cheap multiples. But they're not the right multiples either if the FCF base is about to step higher.

If 2026 revenue comes in near the $620M midpoint and FCF margin holds around 19-20%, that implies roughly $118-124 million in full-year FCF. Add the incremental consumables pull-through from ~40 Atera instruments starting to run in Q4 and into 2027, and 2027 FCF meaningfully exceeds 2026. A rough path: $650M+ revenue with a 20%+ FCF margin gives you $130M+ in FCF.

At 30x FCF — a multiple below where many high-quality recurring-revenue life science tool companies trade — that points to a $3.9B enterprise value, or roughly $4.4B market cap with $500M in net cash. That implies a share price in the mid-$37 to low-$40 range.

From here at $45.60, the upside isn't dramatic. The move already priced a lot of the Atera optimism. But the risk/reward isn't as skewed as the negative EPS headline suggests. The market is simultaneously marking down earnings (which it should) and ignoring the fact that free cash flow is growing at nearly 2x.

The risk that matters

The setup can break in three ways. First, Atera utilization falls materially short of the 2x Xenium estimate — the hardware ships but customers don't run enough samples to drive the consumables step-up. Second, manufacturing ramp delays push meaningful Atera shipments well into 2027, extending the spatial transition revenue trough. Third, academic funding conditions deteriorate further; management described the sentiment as "tenuous" despite improving grant approvals, with multi-year funding structures and staffing delays still suppressing purchasing.

Any one of those would keep the stock range-bound or pull it lower. The APAC revenue collapse of 19% year-over-year in Q2 is a reminder that tariff pull-forward/pull-back dynamics and regional macro risk are real.

The conclusion

This isn't a cheap stock. But the market is pricing it like a company whose earnings are getting worse while it burns through cash, waiting for a product launch that might not land. The actual operating picture — 74% gross margin, $122M in trailing free cash flow, consumables growing while instruments transition, Atera demand exceeding supply — looks like a different animal.

If you own the position, the noise around negative GAAP EPS doesn't change the cash-flow trajectory. The inflection is real but the price action has already done a lot of the work. If you don't, the entry is less compelling than it was at $15 or $25, and the thesis requires patience through Q3 as the spatial transition drag peaks.

The tripwire is simple: if Q3 revenue falls more than modestly sequential and management signals Atera demand is softening, the bridge is broken. If Q4 delivers the Atera shipment step-up and consumables growth holds, the market's current earnings narrative becomes stale.

Discipline over ego either way.